Tyra Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 19, 2024
TYRA$21.15+1.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
ents of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Year EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $62,518 | $43,008 |
| General and administrative (including related party amounts of $0 and $765, respectively) | 17,427 | 15,919 |
| Total operating expenses | 79,945 | 58,927 |
| Loss from operations | (79,945) | (58,927) |
| Other income (expense): | ||
| Interest income | 10,850 | 3,652 |
| Other expense | (39) | (50) |
| Total other income, net | 10,811 | 3,602 |
| Net loss | $(69,134) | $(55,325) |
| Unrealized gain on marketable securities available-for-sale, net | 381 | — |
| Comprehensive loss | $(68,753) | $(55,325) |
| Net loss per share, basic and diluted | $(1.62) | $(1.32) |
| Weighted-average shares used to compute net loss per share, basic and diluted | 42,704,876 | 41,883,904 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.